Internal Medicine, Albany Medical Center, Albany, New York, USA
Internal Medicine, Albany Medical Center, Albany, New York, USA.
BMJ Case Rep. 2021 Dec 22;14(12):e245557. doi: 10.1136/bcr-2021-245557.
Serum sickness (SS) is a known phenomenon; however, it is commonly missed due to vague symptoms, and is usually confounded by other aetiologies that present similarly. Obinutuzumab is a novel anti-CD20 antibody agent that has been approved for chronic lymphocytic leukaemia (CLL) treatment. At the time of approval, it was not linked to SS; however, this phenomenon has been recognised with other anti-CD20 agents like rituximab. SS remains a rare entity, but it is important to be recognised accurately and quickly in the appropriate circumstances, so that effective treatment with corticosteroids can be initiated to alleviate inflammatory symptoms. Here we present a patient with CLL who developed maculopapular rash, fever and polyarthritis and elevated inflammatory markers consistent with serum sickness triggered by obinutuzumab and was effectively treated with corticosteroids.
血清病是一种已知的现象，但由于症状模糊，常被漏诊，且常与其他表现相似的病因混淆。奥滨尤妥珠单抗是一种新型的抗 CD20 抗体药物，已被批准用于治疗慢性淋巴细胞白血病（CLL）。在获得批准时，它与血清病无关；然而，这种现象已在其他抗 CD20 药物如利妥昔单抗中得到认识。血清病仍然是一种罕见的疾病，但在适当的情况下，准确快速地识别它非常重要，以便用皮质类固醇进行有效治疗以缓解炎症症状。在这里，我们介绍了一位 CLL 患者，他出现了斑丘疹、发热和多发性关节炎以及炎症标志物升高，符合奥滨尤妥珠单抗引起的血清病，并用皮质类固醇有效治疗。
